The FDA and CDC have decided to temporarily suspend use of Janssen’s single dose vaccine while reports of rare and severe blood clots are investigated.
List view / Grid view
Filter the results
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
The collaborators hope to make mRNA COVID-19 vaccines accessible to all by creating a shelf-stable, reconstitutable powder formulation.
The spin-out from the Universities of Helsinki and Eastern Finland will leverage years of research to test and bring to market a nasal spray vaccine against COVID-19.
The EU regulator has begun reviewing preclinical and early trial data for Sputnik V, the COVID-19 vaccine developed by Russia.
The trial will evaluate the safety, tolerability and immunogenicity of Ultimovacs’ prostate cancer-specific therapeutic TET-based vaccine.
Dr Caroline Forkin from ICON discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
Research suggests at least a fifth of the US population are resistant to receiving a COVID-19 vaccine, reports suggest this could be due to disinformation and safety concerns.
Scientists call for investment into novel, potentially pan-virus vaccines to prevent the next pandemic
Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
The vaccine was able to target the desired immune cells and could become the first stage of a multi-step vaccine strategy to combat HIV and various other viral diseases.
A preliminary analysis shows VXA-CoV2-1 was well-tolerated and induced T-cell and IgA responses against SARS-CoV-2 antigens in 35 patients.